OTC statin favored
This article was originally published in The Tan Sheet
The National Consumers League says a majority of U.S. consumers with at-risk cholesterol levels (82 percent) would be more likely to consider taking an OTC statin drug than an Rx product. Participants in an NCL survey say an OTC product is more appealing, largely because of convenience factors. They also consider OTC statins safer, more natural, more suitable for people taking charge of their health and less likely to cause side effects than Rx statins. The survey found consumers are three times more likely to seek additional information about an OTC statin than an Rx product (79 percent versus 21 percent). FDA advisory committees on Dec. 13 recommended against approving Merck's third OTC switch application for lovastatin 20 mg (1"The Tan Sheet" Dec. 17, 2007, p. 3)...
You may also be interested in...
More information from "real world" experiences on how consumers make OTC selections may be needed to pull off a successful Rx-to-OTC switch of a statin
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.
A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.